Iron Deficiency Anemia Treatments

Find Iron Deficiency Anemia Treatments

Generic Name

Ferumoxytol

Brand Names

FeraBright, Feraheme

FDA approval date: July 13, 2009

Classification: Parenteral Iron Replacement

Form: Injection

What is FeraBright (Ferumoxytol)?

FERABRIGHT is indicated for magnetic resonance imaging of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier. FERABRIGHT is an iron-based contrast agent indicated for magnetic resonance imaging of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Omega-3 Fatty Acids and Myocardial Inflammation in HFpEF: Preliminary Data and Next Steps

Enrollment Status: Recruiting

Publish Date: June 09, 2026

Intervention Type: Drug

Study Phase: Early Phase 1

Summary: Subjects undergo a gadolinium-based CMR followed by an iron infusion and then a repeat CMR in 72 hours

Trial of Darbepoetin Plus Slow-release Intravenous Iron to Decrease Transfusions and Improve Iron Status and Neurodevelopment in Preterm Infants

Enrollment Status: Recruiting

Publish Date: May 26, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: In this phase II trial, the investigators overarching goal is to demonstrate the feasibility and potential benefit of darbepoetin (Darbe) plus slow-release intravenous (IV) iron to decrease transfusions, maintain iron sufficiency and improve the neurodevelopmental outcomes of preterm infants. Investigators hypothesize that in infants \< 32 completed weeks of gestation, combined treatment with Darb...

Ferumoxytol Enhanced Hippocampal Vascular Imaging in Epilepsy

Enrollment Status: Recruiting

Publish Date: May 08, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: Temporal lobe epilepsy (TLE) is a common type of epilepsy and one of the most likely to not be controlled by medication. For patients who do not respond to medication, surgery can result in a cure of seizures. Given the fact that around 50% of patients who undergo surgery are seizure free at 10 years there is a need to improve the understanding of what factors best predict surgical outcomes in ord...

View All Clinical Trials